Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Edwards Lifesciences (EW)

Analysts from TD Cowen and William Blair have maintained “Buy” ratings for Jazz Pharmaceuticals and Edwards Lifesciences, according to reports released today. Data from TipRanks.com indicates a “Strong Buy” consensus for both companies, with average price targets suggesting an upside of 11.4% for Jazz Pharmaceuticals and 13.6% for Edwards Lifesciences.

Why are analysts bullish on Jazz Pharmaceuticals?

Joseph Thome of TD Cowen maintained a Buy rating on Jazz Pharmaceuticals with a price target of $275.00. The company’s shares closed at $230.81 last Friday. Thome is ranked as a 5-star analyst by TipRanks.com, reporting an average return of 20.6% and a 54.9% success rate.

Other firms share this positive outlook. Truist Financial initiated coverage on June 9 with a Buy rating and a $256.00 price target. The broader market consensus reflects a Strong Buy rating with an average price target of $262.29.

Did You Know? Joseph Thome focuses his healthcare sector coverage on several specific firms, including Rapport Therapeutics, Inc., Amylyx Pharmaceuticals Inc, and MapLight Therapeutics, Inc.

What is the outlook for Edwards Lifesciences?

Brandon Vazquez of William Blair maintained a Buy rating on Edwards Lifesciences. Shares for the company closed last Friday at $83.65. According to TipRanks.com, Vazquez has a 0 on a 0-5 ranking scale, with a 35.2% success rate and an average return of -7.3%.

Despite individual analyst variance, the general market consensus is a Strong Buy. The average price target stands at $98.27. Bank of America Securities also maintained a Buy rating on June 9 with a target of $100.00.

Expert Insight: Samantha Carter notes that while individual analyst track records vary—such as the contrast between a 5-star rating and a 0-star rating—the “Strong Buy” consensus from multiple institutions like Bank of America and William Blair suggests a collective market confidence in these healthcare entities.

What may happen next for these healthcare stocks?

Based on current analyst targets, Jazz Pharmaceuticals shares could move toward the $262.29 consensus average. A rise to Joseph Thome’s $275.00 target would represent a significant increase from the last closing price of $230.81.

Edwards Lifesciences may see a similar trajectory. If the stock reaches the $98.27 consensus target or the $100.00 target set by Bank of America Securities, it would realize the projected 13.6% upside from its $83.65 close.

Frequently Asked Questions

What is the price target for Jazz Pharmaceuticals from TD Cowen?
Joseph Thome of TD Cowen set a price target of $275.00.

What is the analyst consensus for Edwards Lifesciences?
The general consensus is a Strong Buy with an average price target of $98.27.

When did Bank of America Securities issue its rating for Edwards Lifesciences?
Bank of America Securities maintained its Buy rating on June 9.

How do you view the role of analyst ratings when evaluating healthcare stocks?